IRMD vs LMRI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IRMD · IRadimed$86.31 ▲ 0.90%
LMRI · Lumexa Imaging$13.43 ▲ 1.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IRMD -10.3%
- LMRI -27.5%
Head to head
| Metric | IRMD | LMRI |
|---|---|---|
| Price | $86.31 | $13.43 |
| Change today | ▲ 0.90% | ▲ 1.67% |
| Market cap | $1.10B | $1.29B |
| Return, 3 months | -4.2% | +14.4% |
| Return, year to date | -10.7% | -27.4% |
| Return, 1 year | +3.8% | – |
| P/E (TTM) | 46.2 | – |
| P/B | 10.4 | 2.1 |
| P/E percentile vs own 5y | 57th | 16th |
| Dividend yield | 0.89% | – |
| Revenue growth (YoY, latest qtr) | +14.2% | +5.1% |
| Net profit growth (YoY) | +16.7% | +138.0% |
| Gross margin | 75.5% | 14.9% |
| Operating margin | 32.3% | 1.4% |
| Net margin | 26.8% | -2.7% |
| Return on equity | 23.4% | -4.5% |
| Analyst target vs. price | +39.0% | +27.8% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 52 | 76 |
| 30-day volatility | 47.9% | 53.4% |
| Max drawdown, 1 year | -26.7% | -63.5% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LMRI is the largest of the group by market value.
- IRMD is growing revenue fastest.
- IRMD keeps the most profit per dollar of sales.
- IRMD has been the calmest stock over the last 30 days.